Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings.
Victor H FerreiraJavier T SoleraQueenie HuVictoria G HallBerta G ArbolW Rod HardyReuben SamsonTina MarinelliMatthew IerulloAvneet Kaur VirkAlexandra KurtesiFaranak MavandadnejadBeata Majchrzak-KitaVathany KulasingamAnne-Claude GingrasDeepali KumarAtul HumarPublished in: Nature communications (2022)
Immunocompromised patients are predisposed to severe COVID-19. Here we compare homotypic and heterotypic humoral and cellular immune responses to Omicron BA.1 in organ transplant patients across a diverse clinical spectrum. We perform variant-specific pseudovirus neutralization assays for D614G, and Omicron-BA.1, -BA.2, and Delta variants. We also measure poly-and monofunctional T-cell responses to BA.1 and ancestral SARS-CoV-2 peptide pools. We identify that partially or fully-vaccinated transplant recipients after infection with Omicron BA.1 have the greatest BA.1 neutralizing antibody and BA.1-specific polyfunctional CD4 + and CD8 + T-cell responses, with potent cross-neutralization against BA.2. In these patients, the magnitude of the BA.1-directed response is comparable to immunocompetent triple-vaccinated controls. A subset of patients with pre-Omicron infection have heterotypic responses to BA.1 and BA.2, whereas uninfected transplant patients with three doses of vaccine demonstrate the weakest comparative responses. These results have implications for risk of infection, re-infection, and disease severity among immune compromised hosts with Omicron infection.
Keyphrases
- end stage renal disease
- sars cov
- immune response
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- coronavirus disease
- hiv infected
- dendritic cells
- zika virus
- early onset
- copy number
- antiretroviral therapy
- acute respiratory distress syndrome
- respiratory syndrome coronavirus